Form 4: Incyte Corp Executive Sells Shares in Two Transactions

Incyte Corp's Principal Accounting Officer, Thomas Tray, sold 1,300 shares of common stock in two separate transactions.

Summary

• Thomas Tray, the Principal Accounting Officer at Incyte Corp, sold 650 shares of common stock on December 13, 2024, at a price of $70.64 per share.
• He then sold another 650 shares on December 16, 2024, at a price of $69.31 per share.
• Following these transactions, Mr. Tray directly owns 23,312 shares of Incyte Corp common stock, which includes 15,406 unvested restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing regarding stock sales by an executive, which is neither positive nor negative in itself. It's a neutral event.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for all publicly traded companies in the US, and the transactions are within the normal range of insider trading activity.
• Comparable companies such as Gilead Sciences and Vertex Pharmaceuticals also have similar filings when their executives trade company stock.

Stakeholder Impact

• The stock sales by an executive may have a minor impact on shareholder sentiment, but it is unlikely to have a significant effect on the company's operations or financial health.

Key Dates

Keywords

Incyte Corp, insider trading, stock sale, Form 4, Thomas Tray, equity securities, principal accounting officer